Laboratorio de Fisiología y Biología Molecular (LFBM)-IFIBYNE-CONICET, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina.
Neuroimmunomodulation. 2010;17(3):173-6. doi: 10.1159/000258716. Epub 2010 Feb 4.
Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease that destroys the insulin-secreting beta-cells of the pancreas. It is now possible to predict those candidates that will progress to T1D before the full onset of the disease. Prevention of uncontrollable autoimmunity against beta-cells in therapies for T1D is mandatory to preserve the beta-cell mass. Therefore, immunomodulatory strategies directed to inhibiting the activity of self-reactive T cell clones as well as induction of regulatory T cells would be beneficial for prevention of T1D or recurrence of beta-cell autoimmunity against islet cell allografts.
1 型糖尿病（T1D）是一种 T 细胞介导的自身免疫性疾病，可破坏胰腺的胰岛素分泌β细胞。现在已经有可能在疾病完全发作之前预测那些将进展为 T1D 的候选者。在 T1D 的治疗中，防止针对β细胞的不可控自身免疫是维持β细胞质量所必需的。因此，针对抑制自身反应性 T 细胞克隆活性以及诱导调节性 T 细胞的免疫调节策略将有利于预防 T1D 或胰岛细胞同种异体移植物自身免疫的复发。
